Infection prevention
Investigating infection prevention and control Leading experts in their field will present on the latest current and emerging threats and state-of- the-art research to help improve your team, your practice and your patients’ outcomes at Infection Prevention 2019 At the start of the year, the government current antibiotics stay effective by reducing published a 20-year vision and fivethe number of resistant infections and year national action plan for how the supporting clinicians to prescribe appropriately. UK will contribute to containing and The plans include targets such as: cutting the controlling AMR by 2040. number of drug-resistant infections by 10 Antibiotic resistance is predicted per cent (5,000 infections) by 2025; to kill 10 million people reducing the use of antibiotics in every year by 2050 humans by 15 per cent; and “Antim without action. Without preventing at least 15,000 ic robial resistan effective antibiotics, patients from contracting straightforward, infections as a result a dang ce is as big er to hu everyday operations of their healthcare manity as clima like caesarean each year by 2024. t e chang or warf sections or hip New technology will also e are. Tha replacements be used to gather realt w ’s e need why could become time patient data, helping a global r n urgent too dangerous clinicians understand espons to perform. when to use and preserve e.” A major focus of antibiotics in their treatment. the plan is to make sure This could be followed and
adapted all over the world, building the database on antibiotic use and resistance. Cutting antibiotic use Since 2014, the UK has cut the amount of antibiotics it uses by more than seven per cent and sales of antibiotics for use in foodproducing animals have dropped by 40 per cent. But the number of drug-resistant bloodstream infections have increased by 35 per cent from 2013 to 2017. The Department of Health and Social Care also outlined in January how the pharmaceutical industry will be expected to take more responsibility for antibiotic resistance. NICE and NHS England will explore a new payment model that pays pharmaceutical companies based on how valuable their medicines are to the NHS, rather than on the quantity of antibiotics sold. E Issue 19.2 | HEALTH BUSINESS MAGAZINE
49
